Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: A case-control study

Personalized Medicine

Volumn 5, Issue 4, 2008, Pages 361-365

  Subuh Surja, Anton A ^a   Reynolds, Kristen K ^b   Linder, Mark W ^b   El Mallakh, Rif S ^a  

^a University of Louisville School of Medicine   (United States)

^b Jane Phillips Medical Center   (United States)

Author keywords

Adverse drug reaction; Aripiprazole; Bipolar disorder; CYP2D6; Extrapyramidal symptoms; Gene polymorphisms

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; DEXMETHYLPHENIDATE; RISPERIDONE; VALPROATE SEMISODIUM;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CASE REPORT; CHILD; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; HYPERSALIVATION; MALE; MUSCLE STIFFNESS; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RIGIDITY; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; TONGUE DISEASE;

EID: 50549091852     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.4.361     Document Type: Article

References (28)

1. Relling MV, Hoffman JM: Should pharmacogenomic studies be required for new drug approval? Clin. Pharmacol. Ther. 81(3), 425-428 (2007).
2. Kirchheiner J. Brosen K, Dahl ML et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104, 173-192 (2001).
3. Kirchheiner J, Nickchen K, Bauer MI et al.: Pharmcogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
4. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 66(1), 15-27 (2005).
5. Britzi M, Bialer M, Arcavi L,
6. Shachbari A, Kapitulnik T, Soback S: Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther. Drug Monit. 22(5), 510-516 (2000).
7. Aynacioglu AS, Sachse C, Bozkurt A et al.: Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 66(2), 185-192 (1999).
8. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A: Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYN2D6 in Croatian population. Croat. Med. J. 44(4), 425-428 (2003).
9. Tamminga WJ, Wemer J, Oosterhuis B et al.: An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur. J. Clin. Pharmacol. 57(2), 143-146 (2001).
10. Dandara C, Masimirembwa CM, Magimba A et al.: Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol. 57(1), 11-17 (2001).
11. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K: Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br. J. Clin. Pharmacol. 48(3), 395-401 (1999).
12. Burris KD, Molski TF, Xu C et al.: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002).
13. Keck PE Jr, Calabrese JR, McQuade RD et al.: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67, 626-637 (2006).
14. Sachs G, Sanchez R, Marcus R et al.: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20, 536-546 (2006).
15. Abdify®, package insert. Bristol-Myers Squibb, NY, USA (2007).
16. Barzman DH, DelBello MP, Kowatch RA et al.: The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J. Child Adolesc. Psychopharmacol. 14(4), 593-600 (2004).
17. Aparasu RR, Bhatara V: Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr. Med. Res. Opin. 23(1), 49-56 (2007).
18. Singh MK, DelBello MP, Adler CM: Acute dystonia associated with aripiprazole in a child. J. Am. Acad. Child. Adolesc. Psychiatry 46(3), 306-307 (2007).
19. Schonberger RB, Douglas L, Baum CR: Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of new antipsychotic drug aripiprazole. Pediatrics 114(6), 1743 (2004).
20. Lindsey RL, Kaplan D, Koliatsos V, Walters JK, Sandson NB: Aripiprazole and extrapyramidal symptoms. J. Am. Acad. Child Adolesc. Psychiatry 42(11), 1268-1269 (2003).
21. Berecz R, Dorado P, de la Rubia A, Caceres MC, Degrell I. Llerena A: The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets 5(6), 573-579 (2004).
22. Bork JA, Rogers T, Wedlund PJ, de Leon J: A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry 60(7), 469-476 (1999).
23. Brockmöller J, Kirchheiner J, Schmider J et al.: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72(4), 438-452 (2002).
24. Schillevoort I. de Boer A, van der Weide J et al.: Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12(3), 235-240 (2002).
25. Vandel P, Haffen E, Vandel S et al.: Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur. J. Clin. Pharmacol. 55(9), 659-665 (1999).
26. Hendset M, Hermann M, Lunde H, Refsum H, Molden E: Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur. J. Clin. Pharmacol. 63(12), 1147-1151 (2007).
27. Oosterhuis M, van de Kraats G, Tenback D: Safety of aripiprazoie: high serum levels in a CYP2D6 mutated patient. Am. J. Psychiatry 164(1), 175 (2007).
28. Dahl ML: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41(7), 453-470 (2002).